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9 Increasing detection rate of CFTR mutations in routine analysis
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The efﬁcacy of a new molecular screening method for CF, the xTAG® Cystic
Fibrosis 71 v2 kit (Luminex 200), allowing identiﬁcation of 71 CFTR mutations
and 6 polymorphisms, was compared with a routine reference method, the INNO-
LiPA from Innogenetics. The latter consisting on the combination of CFTR17+Tn
Update and INNO-LiPA CFTR19 allows identiﬁcation of 36 mutations and 3 poly-
morphisms. For validation purposes, CF positive and negative DNA samples were
tested in parallel by both methods. Initially, 30 DNA INNO-LiPA positive samples
were analysed by Luminex and results were compared with those obtained by
INNO-LiPA. Wild-type DNA samples (n: 60) were tested by both methods. If
a new substitution was detected, a CFTR exonic sequencing (BDT3.1/3130xl,
Applied Biosystems) was performed. Finally, DNA samples obtained from different
biological matrix (10 samples for each: whole blood, chorionic villi, amniotic ﬂuid
and blood spot from Guthrie cards) were processed by both methods. Whole blood
DNA was extracted by salting-out; foetal DNA and DNA from Guthrie cards, by
phenol-chloroform. Samples were analysed in triplicate by 3 different operators at
3 different days. For all DNA samples, the new and the reference method provided
similar results for each corresponding CFTR mutation. The reproducibility of the
new method was comparable and no signiﬁcant inter-operator variability was noted.
As conclusions, the Luminex kit is a robust CFTR screening method allowing a
twice as large CFTR mutation detection rate and applicable in routine lab analysis.
Currently more than 300 screening tests have been performed by the new method
at our lab.
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CDC’s Newborn Screening Quality Assurance Program (NSQAP) offers proﬁciency
testing (PT) for national and international newborn screening programs that per-
form CFTR mutation detection. Recently, NSQAP, in collaboration with partners,
acquired samples that represent all 23 ACMG recommended CFTR mutations. We
undertook the extensive characterization of these PT materials for single nucleotide
changes, small insertions/deletions, and large insertions/deletions. Samples were
donated by 68 anonymous CF patients or parents. The promoter, exons, splice
sites, portions of all introns, and the 3′ end of the CFTR gene were sequenced.
Large insertions/deletions were identiﬁed using multiplex ligation-dependent probe
ampliﬁcation for all exons. From the sequence data, four samples contained three
potential CF-associated mutations each. We also identiﬁed 32 sequence variations,
four that were previously unidentiﬁed. A subset of these variants was used to
predict haplotypes for many CF causing mutations using the major haplotype
block deﬁned by the HapMap. The F508del mutation was found on a single
haplotype in 58 of the 59 F508del chromosomes. This haplotype was also seen
on 11 non-F508del containing chromosomes, often associated with G542X. These
extensively characterized PT materials are critical to ensure appropriate challenges
and quality of newborn screening laboratory performance. Understanding the
haplotype background of CF associated mutations in the U.S. population provides a
framework for future phenotype/genotype studies. Additionally, the major F508del
haplotype is consistent with previous ﬁndings suggesting a founder effect in ancient
Europe.
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Introduction: Since the identiﬁcation of the CFTR gene in 1989, over 1600 different
molecular defects were recognized and submitted to the Cystic Fibrosis Mutation
Database. The majority of changes described so far are point mutations and small
insertions or deletions. De novo molecular alterations in the CFTR gene have
been previously described but are exceptionally rare. Here we present de novo,
not previously described large deletion spanning exons 12, 13 and 14a.
Material and Methods: Genomic DNA from the patient and his relatives was
extracted from peripheral blood lymphocytes. Molecular analyses of CFTR gene
were carried out using InnoLipa 17 and 19 kits, Asper-206 microarray assay and
MLPA. MLPA results were veriﬁed by long range PCR.
Results: Polish boy of 5 years old, Caucasian origin, was diagnosed as CF at the
age of 6 weeks. He had elevated sweat chloride concentration (>100mmol/l) and
suffered from paroxysmal strenuous cough, recurrent inﬂammation and pancreatic
insufﬁciency. In bacteriological test of pharyngeal swap and trachea aspirate,
Pseudomonas aeruginosa was cultured. A novel deletion of exons: 12, 13 and 14a
was identiﬁed on parental allele. Father of this patient was unaffected suggesting that
the mutation had arisen de novo. On maternal allele he carried F508del mutation.
Conclusions: This case underscores the importance of comprehensive mutation
analysis of CFTR gene. Deﬁnitive identiﬁcation of both mutated CFTR alleles can
conﬁrm the clinical diagnosis and facilitate patient management, carrier testing, and
genetic counseling.
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To evaluate the impact of gene defects of CFTR, PRSS1 and SPINK1 on the
pathogenesis of pancreatitis, a 10 years retrospective review of frequency and type
of such defects was performed in a series of patients with idiopathic pancreatitis.
CFTR experience: A CFTR gene mutation was detected in 40 (9.8%) out of 405
patients screened by routine methods that have increasingly enlarged their mutation
panels: 13 in 1999, 20 up to 2002, 29 up to 2004, 36 up to 2008, and currently
71. The most frequent mutations, F508del (56%) and L997F (18%), were detected
at a greater frequency than that of the general population. The 5T variant (5%)
was associated in comparable proportions with TG11 and TG12 repeats. Sequence
analysis of CFTR exons in carriers allowed identifying 4 compound heterozygous:
F508del/R117H, G542X/L997F, L997F/R75Q and R75Q/R75Q.PRSS1 experience:
A very low frequency (5%) of PRSS1 mutations was found in 21 out of 417 patients
screened by molecular methods that also progressively changed over time from
DGGE of exons 1−3 (from 1999 to 2003), to sequencing of exon 1−3 (from 2004
to 2006), up to sequencing of all coding exons (since 2007). A16V and R122H were
the most frequent mutations found. SPINK1 experience: A low frequency (7.5%)
of SPINK1 mutations was detected in 241 molecular tests: 2 (0.8%) homozygous
and 16 (6.6%) carriers for the N34S mutation. Molecular tests have been upgraded
from enzymatic digestion (from 2002 to 2004) to sequencing of exon 3 in 2005.
The overall frequency of CFTR mutations is in agreement with data from the
literature. However comparatively with other neighbour countries a lower frequency
of mutations was found in two other genes tested.
